Shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) dropped 2.4% during mid-day trading on Thursday . The company traded as low as $1.97 and last traded at $2.02, with a volume of 529,921 shares changing hands. The stock had previously closed at $2.07.

MRNS has been the subject of a number of recent research reports. Jefferies Group reissued a “buy” rating and issued a $2.50 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, June 30th. Stifel Nicolaus reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, June 28th. Royal Bank Of Canada downgraded shares of Marinus Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $14.00 to $2.00 in a report on Tuesday, June 14th. Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Tuesday, July 5th. Finally, Goldman Sachs Group Inc. downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, June 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Marinus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $7.80.

The company’s 50-day moving average is $2.27 and its 200 day moving average is $4.58. The stock’s market capitalization is $37.85 million.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.04. On average, equities analysts predict that Marinus Pharmaceuticals Inc. will post ($1.47) earnings per share for the current fiscal year.

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.